Resolution criteria

This market will resolve to YES if, by 11:59 PM ET on December 31, 2027, a study is published that successfully replicates the primary finding of Hwang et al. (PNAS, 2023).

For the purposes of this market, "successful replication" is defined as a study that:

1. Observes statistically significant elevated levels of WASF3 protein in samples from a cohort of patients diagnosed with ME/CFS compared to healthy controls, consistent with the findings reported in Hwang et al. (2023).

If no such study is published by the specified deadline, the market will resolve to NO.

Background

In August 2023, researchers led by Dr. Paul Hwang published a study in the Proceedings of the National Academy of Sciences (PNAS) titled "WASF3 disrupts mitochondrial respiration and may mediate exercise intolerance in myalgic encephalomyelitis/chronic fatigue syndrome." The study identified that endoplasmic reticulum (ER) stress leads to the overproduction of the WASF3 protein, which subsequently localizes to mitochondria and disrupts the assembly of respiratory supercomplexes. This mechanism was proposed as a contributor to the exercise intolerance and bioenergetic deficiency observed in ME/CFS patients.

The original study utilized a small cohort (n=14) of ME/CFS patients for muscle biopsy analysis and developed transgenic mice to model the effects of WASF3 overexpression. The findings have generated significant interest within the ME/CFS research community as a potential biological basis for hallmark symptoms; however, the scientific community typically requires replication in independent, larger cohorts to validate such findings.

This description was generated by AI, then edited by the market creator.